Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07809945
PHASE1

A Study of IBI3046 in Participants With Overweight or Obesity

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

View on ClinicalTrials.gov

Summary

This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD), IBI3046 administration after mazdutide discontinuation, and IBI3046 in combination with mazdutide

Official title: A Randomized, Double Blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of IBI3046 in Chinese Participants With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

128

Start Date

2026-09-23

Completion Date

2028-10-09

Last Updated

2026-10-19

Healthy Volunteers

No

Interventions

DRUG

IBI3046

subcutaneous injection

DRUG

placebo

subcutaneous injection

Locations (1)

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China